Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SYN-27M
i
Other names:
SYN-27M, IMM27M, IMM-27M, IMM 27M, SYN27M, SYN 27M
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ImmuneOnco Biopharma, Instil Bio
Drug class:
CTLA4 inhibitor
Related drugs:
‹
ipilimumab (223)
tremelimumab-actl (60)
KN046 (19)
cadonilimab (10)
iparomlimab/tuvonralimab (3)
ipilimumab biosimilar (CS1002) (2)
MK-1308 (2)
BNT316 (1)
XTX101 (1)
MEDI5752 (1)
XmAb717 (1)
AI-061 (0)
ATOR-1015 (0)
BMS-986218 (0)
BMS-986288 (0)
BT-001 (0)
CD200AR-L (0)
IBI310 (ipilimumab biosimilar) (0)
INV322 (0)
KD6001 (0)
MT-8421 (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
PF-06753512 (0)
ROSE12 (0)
RP3 (0)
SAL008 (0)
TG6050 (0)
YH001 (0)
XmAb22841 (0)
SI-B003 (0)
MGD019 (0)
ADG126 (0)
HBM4003 (0)
MK-1308A (0)
BMS-986249 (0)
RP2 (0)
ipilimumab (223)
tremelimumab-actl (60)
KN046 (19)
cadonilimab (10)
iparomlimab/tuvonralimab (3)
ipilimumab biosimilar (CS1002) (2)
MK-1308 (2)
BNT316 (1)
XTX101 (1)
MEDI5752 (1)
XmAb717 (1)
AI-061 (0)
ATOR-1015 (0)
BMS-986218 (0)
BMS-986288 (0)
BT-001 (0)
CD200AR-L (0)
IBI310 (ipilimumab biosimilar) (0)
INV322 (0)
KD6001 (0)
MT-8421 (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
PF-06753512 (0)
ROSE12 (0)
RP3 (0)
SAL008 (0)
TG6050 (0)
YH001 (0)
XmAb22841 (0)
SI-B003 (0)
MGD019 (0)
ADG126 (0)
HBM4003 (0)
MK-1308A (0)
BMS-986249 (0)
RP2 (0)
›
Associations
News
Trials
Filter by
Latest
11ms
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=108, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
11 months ago
New P1 trial
|
SYN-27M
over2years
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=16, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Aug 2023
over 2 years ago
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
SYN-27M
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.